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The Helicobacter pylori protein CagA may undergo tyrosine
phosphorylation following its entry into human gastric epithe-
lial cells with downstream effects on signal transduction. Dis-
ruption of the gp130 receptor that modulates the balance of the
SHP2/ERK and JAK/STAT pathways enhanced peptic ulcer-
ation and gastric cancer in gp130 knock-out mice. In this study,
we evaluated the effect of translocated CagA in relation to its
tyrosine phosphorylation status on the gp130-mediated signal
switch between the SHP2/ERK and JAK/STAT3 pathways. We
showed that in the presence of CagA, SHP2 was recruited to
gp130. Phosphorylated CagA showed enhanced SHP2 binding
activity and ERK1/2 phosphorylation, whereas unphosphory-
lated CagA showed preferential STAT3 activation. These find-
ings indicate that the phosphorylation status of CagA affects the
signal switch between the SHP2/ERKand JAK/STAT3pathways
through gp130, providing a novel mechanism to explain H. py-
lori signaling.
Helicobacter pylori frequently colonizes the human stomach
(1), and hosts infected by cagA-positive strains are at increased
risk of gastric cancer and peptic ulceration (2–10). H. pylori
injects the CagA protein into host gastric epithelial cells via a
type IV secretion system (11–16). The injected CagA is tyro-
sine-phosphorylated by Src family protein-tyrosine kinases and
binds SHP2 (Src homology 2 domain-containing Src homology
tyrosine phosphatase) (17–21); the CagA-SHP2 complex has
been detected in human gastric mucosa (22, 23).
The IL6/gp130/STAT3 (interleukin-6/glycoprotein 130/sig-
nal transducer and activation of transcription 3) pathway has
been shown to play a role in the development of gastric cancer
(24, 25). IL6 exerts its biological activities through the receptor
subunit gp130 (26). At least two functional modules of gp130
have been characterized; one encompasses four membrane-
distal Tyr(P) binding sites for the Src homology 2 domain of the
latent transcription factors, STAT1 and STAT3. The other
comprises themembrane-proximal Tyr(P)757 residue responsi-
ble for the engagement of cytoplasmic SHP2 (26, 27).
IL6 induces recruitment and homodimerization of gp130,
potentially leading to balanced signaling through both the JAK/
STAT and SHP2/Ras/ERK signaling pathways (28, 29). How-
ever, disrupting this balance in the gp130 “knock-in” mouse
induced premalignant lesions, including atrophy, intestinal
metaplasia, dysplasia, and ultimately gastric cancer (24). Simi-
larly, when the IL6 cytokine family signaling pathway is dis-
rupted, increased STAT3 signaling may favor development of
gastric adenomas, whereas increased SHP2/ERK2 signaling
may lead to mucosal inflammation (25, 30).
That cellular factors that are up-regulated in response to
H. pylori could modulate SHP2/ERK or JAK/STAT signaling
pathways suggests thatH. pylori persistence and its consequent
pathologies could be influenced by gp130-mediated signal
transduction through these pathways (30). In this study, we
examined the role of CagA tyrosine phosphorylation status in
the activation of the SHP2/ERK and JAK/STAT pathways
downstream of the gp130 receptor. Our studies indicate that
the tyrosine phosphorylation status of CagA produced by
H. pylori directs the traffic of signal transduction through the
two pathways.
EXPERIMENTAL PROCEDURES
Bacteria, Cell Culture, and Co-incubation with H. pylori—A
pair of naturally occurring isogenic cagA strains (147C, with a
3 tyrosine phosphorylation motif, and 147A, without the
motif) isolated simultaneously from the same host have been
described (31–33). As controls, H. pylori strains 60190
(cagPAI), 8822 (cagPAI), and cagA (an isogenic mutant of
60190 lacking cagA (ATCC 49503) were used. H. pylori strains
were cultured on agar plates containing 10% horse serum at
37 °C in a microaerobic atmosphere, using the Campy Con-
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Research Foundation and Korean government (Ministry of Education and
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tainer System (BBL, Sparks,MD).Human (AGS) gastric epithe-
lial cells were cultured in RPMI 1640 medium (Invitrogen),
containing 10% FBS (Invitrogen). The cells were incubated at
37 °C in a humidified atmosphere with 5% CO2. On the day of
experimentation, confluent cells were incubated overnight in
fresh serum- and antibiotic-free media. AGS cells also were
co-incubated with H. pylori up to multiplicities of infection of
100:1 for varying times.
Immunoblotting and Antibodies—Whole cell extracts were
prepared with lysis buffer containing 50 mM Tris (pH 7.5), 5
mM EDTA, 100 mM NaCl, 1% Triton X-100, 1 mM phenyl-
methylsulfonyl fluoride, and protease inhibitors (Roche
Applied Science). Lysates were separated by SDS-PAGE and
transferred to polyvinylidene fluoridemembranes. Immunode-
tectionwas performedusing an electrochemiluminescence rea-
gent (Intron, Seoul, Korea), according to the manufacturer’s
instructions. In experiments using kinase inhibitors, cells were
incubated with PP2 (Calbiochem), UO126 (Promega,Madison,
WI), or AG490 (Calbiochem) for 1 h before co-incubation with
H. pylori. Anti-SHP2, anti-pY99, anti-phospho-STAT3, anti-
STAT3, anti-gp130, anti-phospho-JAK2, anti-JAK2, and anti-
c-Myc were from Santa Cruz Biotechnology, Inc. (Santa Cruz
CA), anti-ERK1/2 and anti-phospho-ERK1/2 were from Cell
Signaling (Danvers, MA), and anti-CagA antibody (HPP-
5003-9) was fromASTRAL Biologicals (San Ramon, CA). Anti-
human IL6Rmonoclonal neutralizing antibody and gp130were
obtained from R&D Systems (Minneapolis, MN). AGS cells
were cultured overnight withmonoclonal antibodies to IL6R or
gp130 (R&D Systems) in a serum-free medium and co-incu-
bated with H. pylori at 37 °C in 5% CO2. Whole cell extracts
were prepared with lysis buffer and analyzed by immunoblot-
ting with antibodies specific for anti-phospho-STAT3 anti-
body. Equal loading of lanes was controlled by comparisonwith
lanes that had been resolved using anti-STAT3 antibody.
Co-immunoprecipitation—For immunoprecipitation, whole
cell extracts prepared with lysis buffer were incubated over-
night with appropriate antibodies for 4 h at 4 °C, and immune
complexes were trapped on protein G-Sepharose beads (Amer-
shamBiosciences). Beadswerewashed five timeswith cold lysis
buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and
protease inhibitors (Roche Applied Science). The cell lysates
and immunoprecipitated materials were subjected to SDS-
PAGE, and then proteins were transferred to polyvinylidene
difluoride membranes and incubated with antibodies, includ-
ing anti-SHP2, anti-CagA, or anti-gp130, and then visualized
using a chemiluminescence reagent (Intron).
Expression Vectors—SHP2-specific small interfering RNA
(siRNA) (kindly provided by Prof. M. Hatakeyama) was used
to silence the expression of SHP2 (34). To selectively knock
down human SHP2 expression, AGS cells were co-trans-
fected with pSUPER-SHP2 and pBabePuro. After 12 h, cells
were incubated in RPMI 1640, 10% fetal bovine serum contain-
ing 0.3 g/ml puromycin (Sigma) to select appropriate trans-
fectants; SHP2 expression of the cloned cells was confirmed by
immunoblotting.
Immunofluorescence Microscopy—AGS cells co-incubated
withH. pylori were washed twice with cold PBS, fixed in meth-
anol for 10min, washed with PBS, and permeabilized with 0.2%
Triton X-100 in PBS for 4 min. Nonspecific binding was
blocked with 3% bovine serum albumin in 0.1% Triton X-100/
PBS for 30 min, followed by incubation with anti-phospho-
STAT3 mouse monoclonal antibodies in 2% bovine serum
albumin, 0.1% Triton X-100/PBS at 4 °C overnight. After wash-
ing with PBS, phospho-STAT3 was visualized by treatment
with fluorescein isothiocyanate-conjugated goat anti-mouse
monoclonal secondary antibodies for 60 min at room temper-
ature. Cells were washed with PBS, mounting medium for fluo-
rescence was added, and slides were sealed with coverslips and
examined for immunofluorescence using a confocal laser-scan-
ning microscope (LSM 510; Carl Zeiss, Thornwood, NY).
Nuclear Protein Extraction and Immunoblotting—AGS cells
co-cultured with H. pylori were harvested and separated into
cytoplasmic and nuclear fractions using CEB buffer (10 mM
Tris-Cl, pH 8, 60 mM KCl, 1 mM EDTA, 1 mM dithiothreitol),
containing 0.5% Nonidet P-40 and protease inhibitors (Roche
Applied Science). The cytoplasmic fraction was clarified by
centrifugation at 1,200 g for 5min, and the nuclear pellet was
washed with CEB buffer containing 0.2% Nonidet P-40 to
remove cytoplasmic contamination. The nuclear pellet was
lysedwithNEB buffer (20mMTris-Cl, pH 8, 0.4 MNaCl, 1.5mM
MgCl2, 1.5 mM EDTA, 1 mM dithiothreitol) containing 0.5%
Nonidet P-40 and protease inhibitors (Roche Applied Science).
Nuclear proteins were analyzed by immunoblotting as described
above.
Real Time PCR—Total cellular RNA was extracted with
TRIzol (Invitrogen) according to the manufacturer’s protocol.
First-strand complementaryDNAwas synthesized from1g of
total cellular RNA using an RNA PCR kit (Intron) with random
primers. Thereafter, real time RT-PCR analysis also was per-
formed using a PCR mixture containing 1 mol/liter of each
primer and SYBR Green master mix (Applied Biosystems, Fos-
ter City, CA) using the ABI PRISM 7000 Quantitative PCR sys-
tem (Applied Biosystems). Each sample was examined in trip-
licate, and the amounts of the PCR products produced were
normalized with respect to -actin, as an internal control. The
following primer pairs were used: c-myc, 5-TGC TCC ATG
AGGAGACACCand 5-CTCTGACCTTTTGCCAGGAG;
-actin, 5-TTGCCGACAGGATGCAGAAGAand 5-AGG
TGG ACA GCG AGG CCA GGA T.
Electromobility Shift Assay (EMSA)—AGS cells co-incubated
with H. pylori were harvested and separated into cytoplasmic
and nuclear fractions using CEB buffer containing 0.5% Non-
idet P-40 and protease inhibitor, as described above. The oligo-
nucleotides used as probes for the EMSAwere as follows: c-myc
E2F, 5-GACGCTTGGCGGGAAAAAG and 5-GGCTTTT-
TCCCGCCAAG (35). Oligonucleotides based on c-myc E2F
were end-labeled with [-32P]ATP by T4 polynucleotide kinase
(Invitrogen). For binding reactions, 1 105 cpm of labeled oligo-
nucleotide probes were incubated with 10 g of nuclear
extracts and 1 g of poly(dI-dC) in binding buffer (4% (v/v)
glycerol, 1 mMMgCl2, 0.5 mM EDTA, 0.5 mM dithiothreitol, 50
mMNaCl, 10mMTris-HCl, pH 7.5) at room temperature for 20
min. Protein-DNA complexes were separated by electrophore-
sis in a 5% non-denaturing polyacrylamide gel in 0.5 TBE
buffer. The gels were dried and exposed to film (Agfa) at70°
using an intensifying screen.
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CellMigration Assay—Cell migration assays were performed
using -Dish 35-mm culture inserts (Ibidi) according to the
manufacturer’s protocols. In brief, AGS cells were seeded into
each well of culture inserts and incubated at 37 °C in a humid-
ified atmosphere with 5% CO2. On the day of experimentation,
confluent cells were refed overnight with RPMI 1640 supple-
mented with 0.5% FBS. After appropriate cell attachment, the
culture inserts were gently removed by using sterile tweezers,
and the dish was filled with fresh RPMI 1640 supplemented
with 0.5% FBS. AGS cells also were co-incubated for 24 h with
H. pylori to a multiplicity of infection of 50.
Statistical Analysis—Significance in differences between
experimental conditions was determined by Student’s t test; p
values of0.05 were considered significant in all analyses.
RESULTS
Role of CagA Tyrosine Phosphorylation Status and SHP2
Binding—The tyrosine phosphorylation status of CagA has
been shown to strongly influence CagA binding affinity to
SHP2 (23, 36). We began our experiments by asking whether
the H. pylori strains that we were studying would show similar
activities. As expected, both of the H. pylori strains (147C and
60190) that express CagA and that have tyrosine phosphoryla-
tion sites in their EPIYA domain (C-EPIYA) showed CagA
binding to SHP2, whereas the CagA PAI-negative 8822 and
cagA strains showed no detectable SHP2 binding (Fig. 1A).
Differences in the mobility of the CagA protein reflect the pre-
viously observed microheterogeneity in the cagA open reading
frame (31, 32). These results confirm that the CagA molecules
we study bind to SHP2, as determined by tyrosine phosphory-
lation status.
Interaction between SHP2 and gp130 in Relation to CagA
Status—SHP2 activation is critical for IL6 induction of the
mitogen-activated protein kinase (MAPK) pathway (34, 37).
IL6 levels in gastric tissue are elevated in H. pylori hosts and
then fall after H. pylori eradication (38). To examine whether
H. pylori affects SHP2 recruitment to gp130, a central constit-
uent of the IL6 receptor complex (37), cellular lysates fromAGS
cells co-incubatedwithH. pyloriwere immunoprecipitated and
immunoblotted using antibodies to CagA, gp130, or SHP2. For
AGS cells co-incubated with C-EPIYA H. pylori strain 147C
or 60190, immunoprecipitation showed that SHP2 was associ-
ated with both gp130 and with CagA. However, no association
with gp130 was detected in the AGS cells that were co-incu-
bated with C-EPIYA H. pylori strain 147A or cagA strain
8822 (Fig. 1B). These data indicate that the injected phosphor-
ylated C-EPIYACagA plays a role in the recruitment of SHP2
to gp130.
Influence of CagA Tyrosine Phosphorylation Status on H. py-
lori-mediated gp130 Receptor Phosphorylation—Next we
compared the isogenic cagA isogenic C-EPIYA 147A and
C-EPIYA 147C H. pylori strains by co-incubating them with
AGS cells to determine whether the AGS cell gp130 receptors
become activated. After co-incubation, the AGS cells were sub-
jected to immunoprecipitation with anti-gp130 antibodies.
Both of the H. pylori strains induced activation of the gp130
receptor, indicating its independence from CagA tyrosine
phosphorylation status.
Influence of CagA Tyrosine Phosphorylation Status on JAK/
STAT3 Activation—Once it became clear that the H. pylori
strains we studied activated gp130, confirming the results of
Bronte-Tinkew et al. (39), we next examined the downstream
JAK/STAT activation. First, to analyze STAT3 activation in
relation to the CagA tyrosine phosphorylation status, AGS cells
were co-incubated for 3 or 6 h with H. pylori strains of varying
cagA genotype and then immunoblotted using anti-phospho-
STAT3. STAT3 was phosphorylated in AGS cells that were
co-incubated with C-EPIYA strain 147A (Fig. 2B), but com-
pared with the absence of H. pylori (control), essentially no
phosphorylation was observed with two C-EPIYA strains
(147C and 60190) or with strain 8822. Following cytokine stim-
ulation, STAT3 is activated by the phosphorylation of a single
tyrosine residue (Tyr705) by JAK2 and dimerizes via a reciprocal
Src homology 2 phosphotyrosine interaction (40). To examine
whether the H. pylori STAT3 phosphorylation is mediated by
JAK2 activation, AGS cells were co-incubated with H. pylori
strains. We found that C-EPIYA strain 147A induced JAK2
activation, which suggests that the STAT3 activation mediated
by non-phosphorylated CagA is dependent on JAK2 activation
(Fig. 2C).
To address that hypothesis, because CagA is phosphorylated
by the Src family of protein-tyrosine kinases (15, 17, 18), we
asked whether pretreatment with PP2, a specific Src family
kinase inhibitor, would affect the CagA-induced STAT3 activa-
tion. AGS gastric epithelial cells were pretreated with PP2 for
1 h prior to co-incubation, and STAT3 activation was exam-
ined. In the presence of PP2, STAT activation by C-EPIYA
strains 147C and 60190 was observed (Fig. 2D). That PP2 inhi-
bition of Src kinase (thus inhibiting CagA phosphorylation)
restores STAT3 activation provides further evidence that non-
phosphorylated CagA is essential for the observed (39) H. py-
lori-induced STAT3 activation.
FIGURE 1. Relationship between the C-EPIYA status ofH. pyloriCagA and
its interaction with SHP2 and gp130. A, lysates of AGS cells co-incubated
withH. pyloriwere immunoprecipitated (IP) with anti-SHP2 or anti-CagA anti-
body and then immunoblotted (IB) with the converse antibodies. Con, con-
trol. B, lysates of AGS cells co-incubated with H. pylori strains for 1 h were
immunoprecipitated with anti-SHP2 antibody. The immunoprecipitates and
total cell lysates (TCL) were immunoblotted with anti-phosphotyrosine, anti-
gp130, anti-CagA, or anti-SHP2 antibody.
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Influence of gp130 and JAK2 Inhibition on CagA-induced
STAT3 Phosphorylation—The IL6 receptor complex is com-
posed of a ligand-binding receptor (IL6R) and its signal trans-
ducer, gp130 (41). Monoclonal antibodies to IL6R and gp130,
that function as specific receptor antagonists, abrogating acti-
vation of the IL6/IL6R/gp130 complex (42), were used to exam-
inewhetherH. pylori-induced STAT3 activation inAGS cells is
mediated through the gp130 receptor. AGS cells were preincu-
bated overnight with the neutralizingmonoclonal antibodies to
IL6R and gp130 in serum-free medium and then co-incubated
with H. pylori.We found that the antibody treatment substan-
tially inhibited the STAT3 activation inAGS cells that had been
induced by strain 147A, which indicated that the predominant
signal by its C-EPIYA CagA involves the gp130 receptor (Fig.
3A). Next, to determine whether the C-EPIYACagA-induced
STAT3 phosphorylation is mediated via JAK2, AGS cells were
pretreated with AG490, a JAK2-preferential JAK inhibitor, and
then co-incubated with H. pylori (Fig. 3B). Importantly, the
addition ofAG490hadno effect on the viability of the cells (data
not shown). AGS cells pretreated with AG490 showed greatly
reduced 147A-mediated STAT3 phosphorylation. In total,
these results showed that both gp130 and JAK2 activation are
involved in the C-EPIYA CagA-induced STAT3 activation.
Influence of C-EPIYA CagA Tyrosine Phosphorylation Status
on SHP2/ERK Activation—The gp130 receptor is responsible
for engagement of cytoplasmic SHP2 and subsequent activa-
tion of the Ras-ERK pathway (26, 27). To investigate whether
CagA C-EPIYA status affects the SHP2/ERK pathway down-
streamof the gp130 receptor, AGS cells were co-incubatedwith
the defined H. pylori strains. As expected, SHP2 was phosphor-
ylated in cells that were co-incubated with C-EPIYA 147C or
60190 and not with C-EPIYA 147C or with cagA 8822 (Fig.
4A). There was early ERK activation by both 147A and 147C,
but activation was more sustained for 147C (Fig. 4B). In the
absence of H. pylori, AGS control cells showed no detectable
levels of phosphorylated ERK1/2. Together with our prior stud-
ies (33), these data confirm that C-EPIYA CagA facilitates
signal transduction through SHP2/ERK to a greater extent than
does C-EPIYA CagA.
To determine why C-EPIYACagA does not induce STAT3
activation and because SHP2 is known to be an important
negative regulator of JAK2/STAT3 signaling in other cells
(42), we next investigated the specific involvement of SHP2
in JAK2/STAT3 activation in AGS cells co-incubated with
H. pylori. SHP2 activity correlates with its own phosphory-
lation, which can catalyze tyrosine phosphorylation of JAKs,
receptors, or other cellular proteins (41). Because we showed
that C-EPIYA strain 147C phosphorylates SHP2 in AGS cells
(Fig. 4A), but JAK2 is not activated (Fig. 2C), and because the
SHP2 recruitment site within gp130 often is involved in nega-
tive regulation of IL6-induced STAT3 activation (43, 44), we
selectively inhibited SHP2 expression using SHP2 siRNA pre-
treatment. As expected, treatment with SHP2 siRNA substan-
tially lowered SHP2 levels (Fig. 4C). In AGS cells that were
co-incubated with C-EPIYA 147A, STAT3 activation was not
affected by the SHP2 siRNA pretreatment. In contrast, siRNA
pretreatment of AGS cells co-incubated with C-EPIYA 147C
increased JAK2 and STAT3. These studies provide further
evidence that phosphorylated SHP2 inhibits JAK2/STAT3
signaling pathways after its interaction with C-EPIYA
FIGURE 2. Relation of gp130 receptor phosphorylation to H. pylori CagA
and STAT3 phosphorylation. A, the gp130 receptor was immunoprecipi-
tated (IP) from the cell lysates with anti-gp130 antibody, and phosphorylated
gp130 receptor was detected by immunoblotting (IB) with anti-phosphoty-
rosine antibody (PY99). The extent of gp130 receptor precipitated then was
assessed by reprobing the blot with an anti-gp130 receptor antibody. B, after
co-incubation with H. pylori strains for 3 or 6 h, STAT3 status was determined
by immunoblotting using antibody recognizing STAT3 phosphorylated at
tyrosine 705 (p-STAT3). The same blot was stripped and reprobed with anti-
STAT3 antibody to assess for gel loading. C, AGS cells were co-incubatedwith
cells of H. pylori strains for the indicated times, and whole cell lysates were
subjected to immunoblot analysis using anti-phospho-JAK2 antibody. The
membrane was reprobed with an anti-JAK2 antibody. D, AGS cells were co-
incubated with cells of H. pylori strains with or without PP2 (10 M) pretreat-
ment andwere examined for STAT3 phosphorylation by immunoblotting. As
a loading control, blots were stripped and reprobed with anti-STAT3 anti-
body. Con, control.
FIGURE 3. Effect of inhibition of gp130 or JAK2 on CagA-induced STAT
activation. A, the AGS cells pretreated overnight in serum-freemediumwith
anti-human IL6R and gp130 neutralizing monoclonal antibodies were co-
incubated with H. pylori cells. Whole cell lysates were subjected to immuno-
blot analysis using phospho-STAT3 (p-STAT3) antibody. Immunoblotting of
total STAT3 served as the control. B, AGS cellswere pretreated (or not)with 20
M JAK2 inhibitor (AG490) for 1 h and then co-incubatedwithH. pylori strains
for 3 h. STAT3 phosphorylation was analyzed by immunoblotting using anti-
p-STAT3 antibody. Con, control.
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CagAmolecules. Thus, phosphorylation-competent (C-EPIYA)
and incompetent (C-EPIYA) forms of CagA have opposing
cellular functions.
ERK kinase activity also can
down-regulate STAT3 function via
several mechanisms, including inhi-
bition of upstream kinases, such as
JAK family members (45), dephos-
phorylation of STAT3 phosphoty-
rosine (46), and formation of an
ERK-STAT3 complex (47). Because
we hypothesized that enhanced
ERK activation in cells co-incubated
with C-EPIYA CagA H. pylori
cells also might lead to STAT3 inhi-
bition, we next investigated in AGS
cells co-incubated with strain 147C
whether the ERK pathway down-
stream from SHP2 was involved in
the STAT3 dephosphorylation. Pre-
treatment ofAGS cells with the ERK
inhibitor U0126 beforeH. pylori co-
incubation clearly enhanced STAT3
activation by 147C or 60190, indi-
cating that C-EPIYA CagA sup-
pressed STAT3 activation via an
ERK-dependentmechanism (Fig. 4D).
Relation of C-EPIYA CagA Status
to STAT3 Nuclear Translocation—
Dimeric STAT3 translocates into
the cell nucleus, where it binds to
defined elements within promoter
regions of target genes, activating
their transcription (48–50). Using
immunoblotting of cytosolic and
nuclear fractions, we investigated
effects on STAT3 translocation in
AGS cells that were incubated
with H. pylori strains of varying
CagA status. Co-incubation with
C-EPIYA strain 147A induced
greater STAT3 nuclear transloca-
tion than the other strains tested
(Fig. 5A). Immunofluorescence anal-
ysis of AGS cells was used to deter-
mine the STAT3 subcellular local-
ization after co-incubation with
H. pylori. AGS cells co-incubated
with 147A induced greater phos-
pho-STAT3 nuclear translocation
than did the cells with either 147C
or the CagA-negative strain (Fig.
5B), consistent with the immuno-
blotting results.
Role of STAT3 on the gp130-
mediated Activation of c-myc—
Next, we examined the conse-
quences of STAT3 activation,which
is mediated by C-EPIYA unphosphorylated CagA, by moni-
toring the protein levels of c-myc, a target gene of STAT3. The
c-myc product is an effector molecule responsible for cell pro-
FIGURE 4. SHP2/ERK activation according to H. pylori CagA status. A, lysates from AGS cells co-incubated
with H. pylori strains were immunoblotted with anti-p-SHP2, and then the membrane was stripped and ana-
lyzed with anti-SHP2 antibody to standardize gel loading. B, AGS cells were co-incubated with cells ofH. pylori
strain 147A or 147C. The phosphorylated ERK1/2 was assessed by immunoblotting. Blots were reprobed with
-ERK antibody to control for differences in ERK1/2 loading (top). Densitometric ratios between p-ERK and ERK
immunoblottingwere shown (bottom). Each bar indicates themean S.E. (error bars) of three separate exper-
iments. *, p 0.05, comparing 147A and 147C. C, AGS cells were transfectedwith SHP2 siRNA or control empty
vector for 12 h and primarily selected for 3 days in RPMI 1640 medium with 10% FBS containing 0.3 g/ml
puromycin. The cells were incubated with control vector alone () or SHP siRNA() and H. pylori. Total cell
lysates were immunoblotted with anti-phospho-JAK2 (p-JAK2), anti-phospho-STAT3 (p-STAT3), or anti-SHP2
antibody. D, AGS cells were pretreated with U0126 (10 M) for 1 h prior to co-incubation with H. pylori. Phos-
phorylation of STAT3 was analyzed by immunoblotting. Con, control.
FIGURE 5. STAT3 phosphorylation and nuclear localization according to the C-EPIYA status of H. pylori
CagA. A, AGS cells were co-incubated with H. pylori strains for 3 h, and then their cytoplasmic and nuclear
fractions were separated. The nuclear proteins were analyzed by immunoblotting with anti-phospho-STAT3
(p-STAT3). To verify complete separation of the cytosolic and nuclear fractions, cytosolic and nuclear extracts
were immunoblotted for aldolase A and lamin B. B, AGS cells were co-incubated with H. pylori cells and exam-
ined using confocal microscopy, with anti-phospho-STAT3 (p-STAT3) stained in green (magnification,100),
and DNA stained with 4,6-diamidino-2-phenylindole.
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liferation and apoptosis (48, 51–54), and STAT3 is known to be
involved in the rapid c-myc activation at least partly by binding
to a site (overlapping the c-myc E2F binding site) within the
c-myc P2 promoter (55, 56). We first performed EMSAs with
oligonucleotide probes containing the STAT3 c-myc E2F bind-
ing site (TTGGCGGGAAA) and/or mut-c-myc E2F, which has
a mutated c-myc E2F site (TTGGAAGTTAA). We examined
nuclear extracts from AGS cells co-incubated with H. pylori to
resolve the binding specificity of the STAT proteins for the
c-myc E2F site. In the IL6 cytokine family-stimulated (control)
cells, nuclear extracts contain STAT3, STAT3/STAT1, and
STAT1 (55). However, our studies showed that STAT3 or
STAT1 homodimers were strongly detected in AGS cells co-
incubated with H. pylori. Nuclear extracts from AGS cells co-
incubated with 147A had STAT3 homodimers bound to the
c-myc E2F binding site, whereas cells co-incubated with 147C
or 60190 had binding of the STAT1 homodimer (Fig. 6A). By
Western blotting, phospho-STAT1 was induced preferentially
in AGS cells co-incubated with 147C or 60190, consistent with
the EMSA results (supplemental Fig. 1).
Next, we examined c-myc mRNA and c-Myc protein levels
by real-time PCR and Western blotting, respectively. As ex-
pected, c-myc mRNA and c-Myc protein expression were
induced by C-EPIYA CagA, paralleling the EMSA findings.
However, c-myc mRNA and c-Myc protein both were down-
regulated in AGS cells co-incubated
with C-EPIYA strain 147C or
60190 (Fig. 6, B and C). To ask
whether c-Myc induction was
STAT3-mediated, we used AG490
to specifically inhibit STAT3 activa-
tion. Pretreatment of AGS cells with
AG490 before co-incubation with
H. pylori affected c-Myc induction,
indicating that STAT3 activation is
involved in the H. pylori-induced
c-Myc response (Fig. 6D).
The C-EPIYA CagA-mediated
JAK/STAT Pathway Induces Cell
Migration—IL6 has an important
role in the initial phase of intestinal
wound healing, and gp130-medi-
ated STAT1/3 signaling has a pro-
tective effect on intestinal epithe-
lium, consistent with STAT3
function in epithelial migration dur-
ing epidermalwoundhealing (57). To
investigate the involvement of the
JAK/STAT pathway in healing of
wounded epithelium in vitro in rela-
tion to the CagA status of H. pylori,
migration assays were performed in
the presence ofH. pylori. There was
significant inhibition of cell migra-
tion by H. pylori strains with
C-EPIYA CagA, whereas cell
migration was induced by H. pylori
with C-EPIYA CagA. To deter-
mine whether C-EPIYA CagA-mediated STAT3 activation
induces cell migration, we also used the JAK2-specific inhibitor
AG490, or IL6/gp130-neutralizing antibody to determine their
effects on cell migration in AGS cells co-incubated with H. py-
lori (Fig. 7). Cell migration induced by H. pylori cells with
C-EPIYA CagA was abolished by inhibition of either JAK or
the gp130 receptor. These data indicate that the JAK/STAT
pathway that is induced by C-EPIYACagAmay participate in
the regulation of cell migration.
DISCUSSION
Gastric colonization with cagA-positive H. pylori strains
increases the risk for atrophic gastritis, peptic ulcer disease,
and gastric cancer (2–6) and may decrease the risk for asthma
and other allergic disorders (58). However, the molecular
mechanisms involved are incompletely understood. In this
study, we used a pair of isogenic strains (147A and 147C)
with identical CagAproteins, differing only by the presence of a
single C-EPIYA motif (31–33) to elucidate the mechanisms by
which tyrosine-phosphorylated CagA affects signaling within
gastric epithelial cells. Because the C-EPIYA (phosphory-
lated) CagA (from 147C) has greater binding affinity to SHP2,
as shown previously (23, 34, 36) and confirmed in our co-im-
munoprecipitation experiments, the extent of this interaction
could affect downstream signaling pathways. For example,
FIGURE 6. Relation of STAT3 activation to the induction of c-myc. A, nuclear extracts from AGS cells co-
incubated with H. pyloriwere incubated with 32P-labeled oligonucleotide containing the c-myc promoter E2F
site and then subjected to electrophoresis and autoradiography. B, AGS cells were co-incubated with H. pylori
for 6 h and expression of c-myc mRNA was analyzed by real-time PCR. C, AGS cells were co-incubated with
H. pylori, and cell lysates were analyzed by Western blot using phospho-STAT3 (p-STAT3) or c-Myc antibody.
The blot was stripped and reprobed with -actin antibody to confirm equal loading. D, cell lysates prepared
fromAGS cells co-incubatedwithH. pylori in thepresenceor absenceof AG490were subjected toWesternblot
using phospho-STAT3 or c-Myc antibody. The blot was stripped and reprobed with STAT3 antibody. Con,
control. Error bars, S.E.
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SHP2 positively regulates ERK
activity, which is necessary for
CagA induction of the humming-
bird phenotype (23). Consistent
with this pathway, we have shown
that phosphorylatedC-EPIYA 147C
CagA induced greater ERK1/2 acti-
vation than did unphosphorylated
C-EPIYA 147A CagA, confirming
our prior observations (33).
However, the IL6 receptor gp130
has bifunctional domains; thus, its
activation can lead to signaling
through either the SHP2/ERK or
JAK/STAT pathways (26, 27). We
asked whether signaling through
these competing transduction path-
ways is affected by CagA in a tyro-
sine phosphorylation (EPIYA)-de-
pendent manner. We first showed
that thegp130 receptor is phosphor-
ylated by CagA, regardless of its
C-EPIYA status. Thus, in addition
to gp130 induction by IL6 in the
human gastric mucosa (38), H. py-
lori also affects gp130-regulated sig-
nal transduction from the interior of
epithelial cells. Next, we found that
C-EPIYA CagA induced substan-
tially more STAT3 than did
C-EPIYACagA, andwe confirmed
the inverse relationship for ERK
activation.
Because STAT3 is activated via
the JAK2 signaling pathway (40), we
sought to determine whether
C-EPIYA CagA-induced STAT3
activation is mediated through the
gp130 receptor. The use of the JAK2
inhibitor AG490 showed that
STAT3 activation by 147A requires
JAK2 activation, and the use of PP2,
a specific inhibitor of Src family
kinases, which blocks CagA phos-
phorylation, restored induction of
STAT3 phosphorylation by 147C or
60190 CagA. Both of these studies
indicate that STAT3 activation is
dependent on C-EPIYA CagA.
That monoclonal antibodies to
IL6R and to gp130 significantly
inhibited STAT3 phosphorylation
in the presence of unphosphory-
lated CagA confirmed the central
role of gp130 in CagA-induced
STAT3 activation. Our findings
consistently indicate that the
gp130/STAT3 pathway is preferen-
FIGURE 7. Effect of STAT3 activation on the migration of AGS cells co-incubated with H. pylori. The cell
migration assay was performed as described under “Experimental Procedures.” AGS cells were co-incubated
with H. pylori in each well of culture inserts in the presence or absence of AG490 or IL6 gp130 neutralizing
antibody and examined using Olympus IX70 microscopy (magnification,100).
FIGURE8.ProposedroleofCagA insignal switchingbetweentheJAK/STAT3andSHP2/ERKpathwaysvia
thegp130receptor inAGScells.AGScells incubatedwithCagAEPIYAH. pylorihavepreferential activation
of the JAK/STAT3 pathway, via the IL6 receptor gp130, whereas AGS cells incubated with CagA EPIYA
H. pylori first tyrosine-phosphorylate CagA and then have preferential activation of the SHP2/ERK pathway.
(The interaction of phosphorylated CagA with SHP2 results in inhibition of gp130-mediated JAK activation.)
Activated JAK recruits STAT3 to the cellmembranegp130complex,which then signals thenucleus via theSTAT
pathway. STAT3 translocated to the nucleus induces c-myc expression and facilitates cell migration, where the
SHP2/ERK pathways, which are predominantly mediated by phosphorylated CagA, induce cell morphological
changes and cell growth inhibition.
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tially activated by C-EPIYA CagA, whereas as expected (11,
23), C-EPIYA CagA preferentially activates the SHP2/ERK
pathway. Thus, the relative proportion of the two forms of
CagA within an H. pylori population may determine the bal-
ance of signaling pathways in the underlying epithelial cells.
Next, we examined why C-EPIYA CagA failed to activate
the STAT3 pathway. ERK kinase activity can down-regulate
STAT3 activation by dephosphorylation of STAT3 phosphoty-
rosine (46), and SHP2 activity can dephosphorylate gp130 and
associated factors, including JAKs and STATs (42). The nega-
tive feedback induced by C-EPIYA CagA on the JAK-related
signal pathway can be explained by down-regulation of the
JAK/STAT signal transduction pathway by several families of
proteins, including ERK, or by SHP2 suppression of the JAK/
STAT pathway. The prolonged STAT3 activity induced by
C-EPIYA CagA also can be explained by prolonged STAT3
phosphorylation through receptor-associated kinases that are
not suppressed by SHP2 as well as by reduced dephosphory-
lation of receptor-recruited JAKs or STATs by SHP2 (59).
Upon stimulation of the IL6 receptor (gp130), STAT3 medi-
ates the rapid activation of c-myc. STAT3 binds to a region
overlapping the E2F site in the c-myc promoter, a locus critical
for c-myc transcriptional activation by IL6 or gp130 signals
(55). To understand the linkage between STAT3 and c-myc
induction, we performed EMSA to analyze whether, in the con-
text ofH. pylori co-incubation, STAT3 binds to the c-myc pro-
moter and performed real time PCR to evaluate STAT3 c-myc
induction. The data show that STAT3 induced in AGS cells by
C-EPIYA CagA binds preferentially to c-myc E2F, whereas
c-myc was not induced in AGS cells co-incubated with
C-EPIYACagAbecause STAT1bound to the c-myc promoter
is likely to interact with a co-repressor. A likely candidate is
MBP-1, which represses c-myc expression when bound to the
E2F site (56). IL6 and HGF activate STAT3 and can promote
epithelial cell growth or migration in vivo (60, 61). In keratino-
cyte-specific STAT3-null mice, slower skin wound healing and
migration defects were observed compared with control mice
(57). In parallel, we provide evidence that STAT3 activation
facilitates gastric epithelial wound healing.
In total, these findings indicate that regulation of human
signal transduction pathways induced by translocated CagA
vary depending on its tyrosine phosphorylation status, with
C-EPIYA CagA playing a novel role. Variation in CagA
C-EPIYA status thus may be responsible for differential gastric
epithelial cell phenotypes. Overall, the tyrosine phosphoryla-
tion status of CagA in H. pylori in part determines the traffic
flows of two opposing pathways, gp130-activated SHP2/ERK
and JAK/STAT signaling, in gastric epithelial cells (Fig. 8).
H. pylori populations in a host are dynamic (62) and can
gain or lose cagA-encoded EPIYA motifs (62) through
recombination involving repetitive DNA sequences (31). Such
changes, whichmay be stochastic with selection determined by
host and environmental circumstances (63), affect epithelial
cell phenotypes that can promote prolonged colonization. The
active role of C-EPIYA CagA in the JAK/STAT pathway
induction now explains the utility to H. pylori of being able to
modify CagA tyrosine phosphorylation status, with the polar
(EPIYA and EPIYA) forms inducing separate and inhibitory
pathways. In this way, the H. pylori population biology with
respect to CagA status, creates a “rheostat,” under selective
pressure, by which the divergent forms affect host cell pheno-
types and ultimately the downstream risk of disease.
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